GLB-001 by GluBio Therapeutics for Myelodysplastic Syndrome: Likelihood of Approval

GLB-001 is under clinical development by GluBio Therapeutics and currently in Phase I for Myelodysplastic Syndrome.

Dec 20, 2023 - 18:00

GLB-001 is under clinical development by GluBio Therapeutics and currently in Phase I for Myelodysplastic Syndrome.

Read the original article

Tags:

Previous Article

GLB-001 by GluBio Therapeutics for Refractory Acute Myeloid Leukemia: Likelihood...

UI-059 by Korea United Pharm for Reflux Esophagitis (Gastroesophageal Reflux Dis...

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

Opinion: In defense of being ‘Cali sober’

Opinion: In defense of being ‘Cali sober’

May 31, 2023

ODAIA wins $25m funding to boost commercial insights platform for pharma

ODAIA wins $25m funding to boost commercial insights pl...

May 2, 2023

Bristol Myers Squibb’s Breyanzi receives EC approval to treat LBCL

Bristol Myers Squibb’s Breyanzi receives EC approval to...

May 4, 2023